In a study of 4607 ATM pathogenic variant carriers and 623,135 controls, variant carriers reported a personal history of ductal invasive breast cancer (33.4%), prostate cancer (32.8%), ovarian cancer (4.4%), colorectal cancer (2.9%), and pancreatic cancer (1.4%). This evidence concerns the gene ATM and prostate carcinoma.